{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:05:32Z","timestamp":1793221532372,"version":"4.5.0"},"reference-count":28,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2019,7,1]]},"DOI":"10.1001\/jamainternmed.2019.0583","type":"journal-article","created":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T11:04:22Z","timestamp":1559041462000},"page":"915","source":"Crossref","is-referenced-by-count":146,"title":["An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate"],"prefix":"10.1001","volume":"179","author":[{"given":"Emerson Y.","family":"Chen","sequence":"first","affiliation":[{"name":"Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Raghunathan","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland"},{"name":"Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"21","key":"ioi190022r1","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1001\/jama.2017.14896","article-title":"The FDA\u2019s expedited programs and clinical development times for novel therapeutics, 2012-2016.","volume":"318","author":"Hwang","year":"2017","journal-title":"JAMA"},{"key":"ioi190022r2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1634\/theoncologist.13-S2-19","article-title":"Endpoints for assessing drug activity in clinical trials.","volume":"13","author":"Pazdur","year":"2008","journal-title":"Oncologist"},{"issue":"9","key":"ioi190022r3","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1200\/JCO.2014.59.0489","article-title":"Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.","volume":"33","author":"Blumenthal","year":"2015","journal-title":"J Clin Oncol"},{"issue":"7","key":"ioi190022r4","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1634\/theoncologist.2017-0152","article-title":"Oncology drug approvals: evaluating endpoints and evidence in an era of breakthrough therapies.","volume":"22","author":"Blumenthal","year":"2017","journal-title":"Oncologist"},{"issue":"6","key":"ioi190022r5","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1001\/jamaoncol.2017.5618","article-title":"A 25-year experience of US Food and Drug Administration accelerated approval of malignant hematology and oncology drugs and biologics: a review.","volume":"4","author":"Beaver","year":"2018","journal-title":"JAMA Oncol"},{"issue":"2","key":"ioi190022r6","first-page":"22","article-title":"The changing world of cancer drug development: the regulatory bodies\u2019 perspective.","volume":"3","author":"Gravanis","year":"2014","journal-title":"Chin Clin Oncol"},{"issue":"13","key":"ioi190022r7","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/j.ejca.2014.05.024","article-title":"Progression-free survival as an end-point in solid tumours\u2014perspectives from clinical trials and clinical practice.","volume":"50","author":"Robinson","year":"2014","journal-title":"Eur J Cancer"},{"issue":"10","key":"ioi190022r8","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1158\/1078-0432.CCR-05-2574","article-title":"Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.","volume":"12","author":"Iacobucci","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"2","key":"ioi190022r9","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1182\/blood.V94.2.429","article-title":"Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin\u2019s disease and non-Hodgkin\u2019s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.","volume":"94","author":"Jerusalem","year":"1999","journal-title":"Blood"},{"issue":"8","key":"ioi190022r10","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"25","key":"ioi190022r11","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma.","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"issue":"28","key":"ioi190022r12","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.","volume":"27","author":"Friedman","year":"2009","journal-title":"J Clin Oncol"},{"issue":"21","key":"ioi190022r13","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"ioi190022r14","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J Clin Oncol"},{"issue":"17","key":"ioi190022r15","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1200\/JCO.2011.39.5848","article-title":"Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.","volume":"30","author":"Socinski","year":"2012","journal-title":"J Clin Oncol"},{"key":"ioi190022r16","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-update and clarification: from the RECIST committee.","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"issue":"1","key":"ioi190022r17","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"issue":"10","key":"ioi190022r18","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/cncr.v123.10","article-title":"Meaningful endpoints for therapies approved for hematologic malignancies.","volume":"123","author":"Smith","year":"2017","journal-title":"Cancer"},{"issue":"8","key":"ioi190022r19","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1377\/hlthaff.2012.0541","article-title":"An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987-2011.","volume":"32","author":"Lanthier","year":"2013","journal-title":"Health Aff (Millwood)"},{"issue":"1","key":"ioi190022r20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019.","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"issue":"14","key":"ioi190022r21","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"issue":"10","key":"ioi190022r22","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-Term outcomes of imatinib treatment for chronic myeloid leukemia.","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"ioi190022r23","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1182\/blood-2010-09-307645","article-title":"Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients.","volume":"117","author":"Gay","year":"2011","journal-title":"Blood"},{"issue":"6","key":"ioi190022r24","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.jval.2013.07.004","article-title":"Complete cytogenetic response and major molecular response as surrogate outcomes for overall survival in first-line treatment of chronic myelogenous leukemia: a case study for technology appraisal on the basis of surrogate outcomes evidence.","volume":"16","author":"Oriana","year":"2013","journal-title":"Value Health"},{"key":"ioi190022r25","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ejca.2018.11.012","article-title":"A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology.","volume":"106","author":"Haslam","year":"2019","journal-title":"Eur J Cancer"},{"issue":"8","key":"ioi190022r26","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1001\/jamainternmed.2015.2829","article-title":"The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses.","volume":"175","author":"Prasad","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"23","key":"ioi190022r27","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma.","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N Engl J Med"},{"issue":"19","key":"ioi190022r28","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1056\/NEJMp1803602","article-title":"Immunotherapy combinations in multiple myeloma\u2014known unknowns.","volume":"379","author":"Gormley","year":"2018","journal-title":"N Engl J Med"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamainternalmedicine\/article-pdf\/179\/7\/915\/17690761\/jamainternal_chen_2019_oi_190022.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T11:50:29Z","timestamp":1574769029000},"score":1,"resource":{"primary":{"URL":"http:\/\/archinte.jamanetwork.com\/article.aspx?doi=10.1001\/jamainternmed.2019.0583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,1]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2019.0583","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7,1]]}}}